Kaken, JP3207000005

Kaken updates 2026 ESG data: Kaken Pharmaceutical stock posts JPY 30.15 billion

Published on 10/20/2026 at 01:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kaken updated ESG data on September 30, 2026. Kaken Pharmaceutical stock posted JPY 30.15 billion in first-quarter revenue.

Company figures and reporting context

Kaken updated its ESG data and published its 2026 integrated report on September 30, 2026.
First-quarter revenue reached JPY 30.15 billion and net income reached JPY 8.44 billion on August 7, 2026.
Fiscal-year 2027 guidance calls for JPY 89.90 billion in sales and JPY 7.90 billion in operating profit.
Kaken had a JPY 144.3 billion market capitalization as of October 19, 2026.

Kaken, JP3207000005, Illustration mit AI erstellt.

Kaken Pharmaceutical updated its ESG data and published its Integrated Report 2026 on September 30, 2026, according to the company's Kaken Pharmaceutical investor-relations page. The disclosure gives investors a fresh corporate reporting reference while the latest operating figures remain tied to the company's first quarter of fiscal 2027.

ESG update adds a reporting reference

The September 30, 2026 update covered Kaken's ESG data, while the same investor-relations platform lists the 2026 integrated report among its latest materials. The company develops, manufactures and commercializes pharmaceutical products, medical devices and agricultural chemicals, with operations centered in Japan and additional global licensing activity.

What does first-quarter revenue show?

Revenue reached JPY 30.15 billion and net income reached JPY 8.44 billion in the first quarter of fiscal 2027, released on August 7, 2026, according to Investing.com. Revenue rose 59.80 percent from JPY 19.25 billion in the comparable prior quarter, while net income increased from JPY 0.75 billion to JPY 8.44 billion. The comparison matters because the reported profit included a substantial contribution from licensing-related income, making the quality and repeatability of earnings important for later periods.

Guidance sets the next benchmark

For the fiscal year ending March 2027, Kaken's guidance calls for JPY 89.90 billion in net sales, JPY 7.90 billion in operating profit, JPY 6.50 billion in profit attributable to owners of the parent and basic earnings per share of JPY 171.65, according to JPX Market Explorer. First-quarter net income already exceeded that full-year guidance figure, but one quarter does not establish the pace for the entire year.

Three dated company milestones

On May 22, 2026, Kaken provided fiscal-year 2027 guidance of JPY 89.90 billion in sales. On August 7, 2026, it reported JPY 30.15 billion in first-quarter revenue and JPY 8.44 billion in net income. On September 30, 2026, it updated its ESG data and published its 2026 integrated report.

Market context for Kaken

Kaken's Tokyo Stock Exchange close was JPY 3,845 on October 16, 2026, while its market capitalization was JPY 144.3 billion as of October 19, 2026. The dated market figures place the operating update in a valuation context without changing the company's central question: whether first-quarter earnings can translate into sustained full-year performance.

Stock context and company facts

Kaken Pharmaceutical trades under ticker 4521 on the Tokyo Stock Exchange. Its portfolio includes treatments for fungal nail infections, osteoarthritis, skin ulcers and periodontal tissue regeneration, alongside agricultural and animal-health products.